EMA 2015 budget up as pharmacovigilance fees kick in; Rasi becomes 'principal adviser'
This article was originally published in SRA
Executive Summary
At least someone has managed to secure an increase in their spending power for the coming year, despite the straitened economic times. The European Medicines Agency's budget for 2015 has been set at just over €302m, up by 7% over the 2014 figure of €282.5m1. In other EMA-related news, Guido Rasi, who stepped down as executive director of the agency last month2, has just been made principal adviser in charge of strategy and is continuing to play a key role.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.